Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome

Area of Science:

• Oncology
• Medical Oncology
• Pharmacology

Background:

• First-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard for advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC), outperforming chemotherapy.
• Real-world scenarios often reveal EGFR mutations after chemotherapy initiation, necessitating strategic treatment adjustments.

Purpose of the Study:

• To review clinical evidence for first-line EGFR TKI treatment strategies in advanced EGFR-mutant NSCLC.
• To discuss optimal treatment sequencing when EGFR mutation status is determined after chemotherapy has begun.

Main Methods:

• Literature review of clinical studies and trials.
• Analysis of treatment strategies including EGFR TKI sequencing, maintenance, and combination therapies.

Main Results:

• First-line EGFR TKIs demonstrate superior response rates, progression-free survival, and quality of life compared to chemotherapy.
• Various strategies exist for managing delayed EGFR mutation results, including switching, maintenance, or combined therapies.

Conclusions:

• Optimizing the sequence of EGFR TKIs in advanced EGFR-mutant NSCLC is crucial, especially when mutation status is confirmed post-chemotherapy initiation.
• Further research is needed to establish the most effective treatment algorithms for these complex clinical situations.